1. |
Joan HM. Hormone receptors and breast cancer. Human Pathol, 1981; 12(12)∶1057.
|
2. |
Nakatsuka I, Ferreira NL, Eckelman WC, et al. Synthesis and evaluation of (17α, 20E)21〔125I〕iodo19norpregna1,3,5(10), 20tetraene3, 17diol and (17α, 20E)21〔125I〕iodo11βmethoxy19norpregna1,3,5(10), 20tetraene3, 17diol 17α(iodovingl) estradiol derivatives as high specific activity potential radiopharmaceuticals. J Med Chem, 1984; 27(10)∶1287.
|
3. |
Eckelman WC, Reba RC, Gibson RE, et al. Receptor binding radiotracers: a class of potential radiopharmaceuticals. J Nucl Med, 1979; 20(2)∶350.
|
4. |
EU PJ, Khan O. Emission computerised tomography: clinical application. Semi in Nucl Med, 1981; 11(1)∶50.
|
5. |
Cummins CH. Radiolabeled steroid estrogens in cancer research. Steroid, 1993; 58(2)∶245.
|
6. |
Symes EK, Bishop PB, Coulson WF, et al. 17αZ〔125I〕 iodovingloestradiol and its 3acetate: chemical synthesis and in vivo distribution studies in the rat. Biochem Parmacol, 1992; 44(4)∶741.
|
7. |
Zeicher M, Delcorde A, Quivy J, et al. Radioimaging of human breast carcinoma xenografts in mice by 〔123I〕lebeled Z17αiodovingl11βchloromethy estradiol. Nucl Med Biol, 1996; 23(1)∶69.
|
8. |
McManaway ME, Jagodo EM, Kasid A, et al. 〔125I〕17αiodovingl 11βmethoxyestradiol interaction in vivo with estrogen receptors in hormoneindependent MCF7 human breast cancer transfected with the VrasH oncogene. Cancer Res, 1987; 47(11)∶2945.
|